Related Experiment Video

Updated: Aug 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Intermediate- to high-risk prostate cancer patient treated with radiation therapy

E David Crawford¹, Al Barqawi

¹University of Colorado Health Sciences Center, Denver, USA.

Oncology (Williston Park, N.Y.)

|October 9, 2004

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

Clinical genitourinary cancer·2026

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

JCO oncology practice·2024

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Cancer·2024

Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Cancer medicine·2024

Germline genetic testing for prostate cancer: Ordering trends in the era of expanded hereditary cancer screening recommendations.

Urologic oncology·2024

See all related articles